Business Strategy Lonza Joins Medicines Manufacturing Research Centre CMAC

Related Vendors

Lonza Ltd.

DÜPERTHAL Sicherheitstechnik GmbH & Co. KG

Italvacuum, Srl

TRM Filter d.o.o.

With an aim to enhance its service offering for particle technologies and drug product development and manufacture, Lonza has joined CMAC, an international research hub with a unique configuration of academic and industrial leaders within applied and pre-competitive research programs, and translation to industry models.

Basel/Switzerland – Lonza has recently announced that it has joined CMAC, a world leading centre for medicines manufacturing research, to enhance its service offering for particle technologies and drug product development and manufacture. Based at the University of Strathclyde in Scotland, CMAC is an international research hub with a unique configuration of academic and industrial leaders within applied and pre-competitive research programs, and translation to industry models. Driven by industry needs, it aims to transform pharmaceutical manufacturing and crystallization processes by developing continuous manufacturing technologies, optimizing efficiency, and enhancing product quality.

Through its membership, Lonza will gain access to CMAC’s unique network, which advances Chemistry, Manufacturing and Control (CMC) technologies, implements digitalization strategies and develops innovative continuous processing and crystallization solutions for active pharmaceutical ingredients and drug product technologies. Lonza’s participation in CMAC will ensure the effective application of research outcomes to strengthen CMC processes and their implementation for its customers.

Massimo Bresciani, CMAC Industry Director, commented: ‘‘Welcoming Lonza into CMAC marks a significant milestone in our mission to transform medicines manufacturing. Its global leadership, technical depth, and strategic vision will be instrumental in shaping and accelerating the adoption of highly automated manufacturing platforms and advanced CMC solutions. This collaboration reinforces our commitment to building a connected ecosystem where academic innovation and industrialists converge to translate cutting-edge research into impactful, scalable solutions for the pharmaceutical and biotech sectors.’’

Francois Ricard, Head of R&D, Advanced Synthesis, Lonza, added: “Our participation in CMAC will allow us to work with world-leading industry and academia experts and apply best practice in the fields of API development, continuous processing, drug product development, and overall digital CMC strategy. Our global team will drive the implementation of these processes and technologies across scales in a CDMO setup for the benefit of our customers and partners.”

Major reallocation of healthcare services during the COVID-19 pandemic meant that elective surgery in children with congenital heart disease (CHD) was significantly reduced, so that those needing urgent, lifesaving and emergency surgery could be treated. However, this prioritisation of the most severely ill children did not increase overall post-operative complications rates or death, a study led by the University of Bristol has shown.

(ID:50390926)